MAYNF (Mayne Pharma Group) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 11, 2026)


MAYNF Mayne Pharma Group Ltd MAYNF
52 GF Score
Price $1.97
GF Value $3.70
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group 5-Year Yield-on-Cost %?

Mayne Pharma Group MAYNF 52 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus rates MAYNF with a GF Score™ of 52/100 and a GF Value™ of $3.70 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 69 Medical Distribution companies, Mayne Pharma Group ranks worse than 1449273.91% on this metric.

Mayne Pharma Group's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Mayne Pharma Group's 5-Year Yield-on-Cost % or its related term are showing as below:



MAYNF's 5-Year Yield-on-Cost % is not ranked *
in the Medical Distribution industry.
Industry Median: 3.25
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Mayne Pharma Group  (OTCPK:MAYNF) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Mayne Pharma Group 5-Year Yield-on-Cost % Related Terms


MAYNF vs MCK, CAH, COR: 5-Year Yield-on-Cost % Comparison

For the Medical Distribution subindustry, Mayne Pharma Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mayne Pharma Group 5-Year Yield-on-Cost % vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's 5-Year Yield-on-Cost % falls into.


MAYNF
52GF Score
Mayne Pharma Group Ltd MAYNF
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mayne Pharma Group 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Mayne Pharma Group is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Mayne Pharma Group (MAYNF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #999999 out of 69 companies in the Medical Distribution industry.
Is Mayne Pharma Group's 5-Year Yield-on-Cost % too high?
Mayne Pharma Group's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Mayne Pharma Group ranks #999999 out of 69 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's 5-Year Yield-on-Cost % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #999999 out of 69 companies for 5-Year Yield-on-Cost %. This places Mayne Pharma Group in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.25, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.70, compared to a current price of $1.97 — trading 46.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Mayne Pharma Group's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mayne Pharma Group (MAYNF) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of $1.97 is trading 46.7% below its estimated GF Value™ of $3.70. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for MAYNF:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $3.70 vs. price of $1.97 (46.7% below fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mayne Pharma Group Business Description

Other Exchanges MYX:Australia
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
52GF Score

Get the complete analysis for MAYNF

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.97
Price
$3.70
GF Value